Tag: FDA
Complex Generic Formulations: Why Proving Bioequivalence Is So Hard
Jan 10 2026 / MedicationsProving bioequivalence for complex generics like inhalers, creams, and patches is far harder than for regular pills. Without blood-level tests, manufacturers face reverse-engineering challenges, unstable formulations, and conflicting global standards - delaying affordable alternatives.
VIEW MORE